UNSPSC 51152012: Pipecuronium

This classification denotes a muscle relaxant with the molecular formula C35H62N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6ZTY81RE1, chemically known as 4,4-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1,1-dimethylpiperazinium)dibromide, diacetate (ester) but generally known as pipecurium bromide, which bears US NIH Compound Identifier 65332. European Medicines Agency schedules Pipecuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14880MIG.

UNSPSC 51152012 Pipecuronium is a Commodity code, but the recent state and local opportunities tagged under it show a substantial mismatch: the code nominally describes a pharmaceutical agent, yet the actual procurements involve naloxone (an opioid antagonist) and drug deactivation systems for emergency response, plus preliminary market research into direct-to-manufacturer prescription fulfillment models. State and local governments do not appear to be actively procuring pipecuronium itself under this code. The issuing bodies include county health departments and state health and human services commissions, but the recent opportunities reflect narrow, specialized pharmaceutical and pharmacy-operations sourcing rather than a broad commodity family. Neither solicitation targets conventional pharmaceutical procurement channels or vendor bases.

The geographic activity centers on Florida and Texas. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023—noting a significant date inconsistency in the source. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) on April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs serving self-insured state employee group health plans and local government health plans, with no formal bid deadline or contract value specified as of the RFI stage. The code shows minimal recent activity and lacks meaningful alignment between its nominal scope and the actual work being bought, suggesting limited opportunity concentration under this taxonomy entry.